Skip to main content
Kenneth Mahaffey, MD, Cardiology, Stanford, CA

KennethWMahaffeyMD

Cardiology Stanford, CA

Adult Congenital Heart Disease

Associate Professor, Medicine, Duke University School of Medicine

Dr. Mahaffey is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Mahaffey's full profile

Already have an account?

  • Office

    300 Pasteur Dr
    Stanford, CA 94305
    Phone+1 650-723-4000
    Fax+1 650-498-5840

Education & Training

  • Duke University Hospital
    Duke University HospitalFellowship, Cardiovascular Disease, 1993 - 1996
  • University of Arizona College of Medicine-Tucson
    University of Arizona College of Medicine-TucsonResidency, Internal Medicine, 1989 - 1993
  • University of Washington School of Medicine
    University of Washington School of MedicineClass of 1989

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2014 - 2026
  • NC State Medical License
    NC State Medical License 1996 - 2022
  • AZ State Medical License
    AZ State Medical License 1993 - 1994
  • American Board of Internal Medicine Cardiovascular Disease

Awards, Honors, & Recognition

  • Fellow (FACC) American College of Cardiology

Publications & Presentations

PubMed

Journal Articles

  • Alirocumab and Cardiovascular Outcomes After Acute Coronary Syndrome  
    Vera A Bittner, Kenneth W Mahaffey, Deepak L Bhatt, Robert A Harrington, Gregory G Schwartz, Matthew T Roe, The New England Journal of Medicine
  • Cardiovascular Outcomes After Lower Extremity Endovascular or Surgical Revascularization  
    Kenneth Mahaffey, Manesh R Patel, W Schuyler Jones, William R Hiatt, Jeffrey S Berger, ScienceDirect
  • Impact of Lesion Complexity on Peri-Procedural Adverse Events and the Benefit of Potent Intravenous Platelet Adenosine Diphosphate Receptor Inhibition After Percutaneo...  
    Gregg W Stone, Matthew J Price, Philippe Genereux, C Michael Gibson, Deepak L Bhatt, Robert A Harrington, Kenneth W Mahaffey, European Heart Journal
  • Join now to see all

Lectures

  • Shark Tank Judge 
    2019 ACC Scientific Session & Expo, New Orleans - 3/18/2019
  • Effects of Canagliflozin on Heart Failure Outcomes With and Without Preserved Ejection Fraction in Type 2 Diabetes: Results From the CANVAS Program 
    2019 ACC Scientific Session & Expo, New Orleans - 3/17/2019
  • ROCKET-AF: Rivaroxaban Prevents Stroke as Effectively as Warfarin, With Lower Bleeding Risk 
    American Heart Association, Scientific Sessions 2010, Chicago, Illinois, USA
  • Join now to see all

Authored Content

  • 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical TrialsMarch 2017

Press Mentions

  • Chinese Medicine Tongxinluo Yields ‘Surprising’ Benefits Post-STEMI: CTS-AMI
    Chinese Medicine Tongxinluo Yields ‘Surprising’ Benefits Post-STEMI: CTS-AMINovember 10th, 2022
  • Chinese Herbal Medicine May Offer Benefits in STEMI: CTS-AMI
    Chinese Herbal Medicine May Offer Benefits in STEMI: CTS-AMINovember 7th, 2022
  • How Sweet We Need It
    How Sweet We Need ItMay 30th, 2022
  • Join now to see all

Professional Memberships